ODYY - Odyssey Health Inc. (ODYY) Determined to Introduce the Market's First FDA Approved Concussion Treatment Drug
- PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion
- Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions
- Once approved, Odyssey is confident that PRV-w002 will bring relief to thousands of victims, reduce the cost of concussion treatment and allow victims to lead normal, healthy, and productive lives
- The company is currently scheduling a meeting with the FDA to present findings from the phase I trial, as it identifies phase II trial sites and creates the study design for other subsequent studies
According to the University of Michigan Health, every year in the United States, there are about 3.8 million concussions from sports-related injuries. The Center for Disease Control (“CDC”) further estimates that 5-10% of athletes will experience a concussion in any given sports season, with most of these injuries going undiagnosed or even unreported (https://ibn.fm/ofqNR).
The economic impact of these conditions is significant, with PBS News Hour estimating it to be between $446 million and $1.5 billion a year for individuals in college. In contrast, for high school students, the...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.